Nicotinic acetylcholine receptor alpha-6 beta-2 (nAChR alpha-6 beta-2) (nAChR alpha-6 beta-2)

The nicotinic acetylcholine receptor alpha-6 beta-2 (alpha6beta2*) is a pentameric ligand-gated ion channel predominantly localized in the dopaminergic pathways of the central nervous system, specifically within the substantia nigra and ventral tegmental area [1, 4]. Unlike the more widely distributed alpha4beta2 subtype, alpha6beta2* receptors exhibit a restricted expression pattern, primarily on the presynaptic terminals of dopaminergic neurons where they modulate the release of dopamine in the striatum and nucleus accumbens [3, 7]. This specific localization makes the alpha6beta2* receptor a high-priority therapeutic target for neurological and psychiatric conditions involving dopaminergic dysfunction, such as Parkinson's disease and nicotine addiction [2, 9]. In Parkinson's disease, targeting these receptors may provide neuroprotection or alleviate L-DOPA-induced dyskinesias, while in addiction, they mediate the reinforcing effects of nicotine [3, 8]. Current pharmacological strategies include the use of partial agonists like varenicline to reduce withdrawal symptoms and antagonists to block the rewarding effects of nicotine [1, 11]. However, achieving high selectivity for the alpha6beta2* subtype over other closely related nicotinic receptors remains a significant challenge in drug development [2, 6].

Other names

alpha6beta2* nAChRCHRNA6/CHRNB2 receptoralpha6-beta2 nicotinic receptorNeuronal acetylcholine receptor alpha-6 beta-2

Agonism or partial agonism at the alpha-6 beta-2 interface stimulates the release of dopamine in the striatum and nucleus accumbens [1, 3]. Antagonism at this site blocks the reinforcing effects of nicotine [11]. Chronic exposure to agonists leads to receptor desensitization and subsequent up-regulation of receptor density [5, 15].